Compounded semaglutide and tirzepatide: what's real, what's hype

What did @haleighweaver5 actually say?

The claim here is brief but carries weight. The creator says she had "gone up to like 80 units at one point" of what the video caption identifies as compounded semaglutide or tirzepatide, and frames this as her personal high-water mark. She's not giving a tutorial, but the context, a reply about affordable compounded GLP-1s for weight loss, makes this a dosing reference that viewers will treat as informational.

The problem is that "units" is not the standard measurement for semaglutide or tirzepatide dosing. These drugs are typically measured in milligrams. Insulin is measured in units. This distinction is not trivial. Confusing the two measurement systems in the context of injectable medications is exactly the kind of slip that has contributed to serious medication errors in real clinical settings.

Does the science back this up?

There is no published clinical protocol for semaglutide or tirzepatide dosed in "units." This is not a minor terminology quibble. The FDA-approved dosing for semaglutide (Wegovy) tops out at 2.4 mg weekly. Tirzepatide (Zepbound) reaches a maximum of 15 mg weekly. Neither drug is expressed in units in any manufacturer labeling or peer-reviewed literature.

The confusion may stem from how some compounding pharmacies package these drugs. Compounded semaglutide is often supplied in vials where patients self-administer using insulin syringes, which are calibrated in units. A patient drawing 80 units on an insulin syringe could be drawing anywhere from 0.8 mg to several milligrams depending on the vial concentration. Concentration varies between compounding pharmacies and is not standardized. Bhatt et al. (2022, NEJM) and the broader STEP trial series established efficacy and safety at specific mg doses, none of which were described in units.

What did they get wrong (or right)?

The creator gets credit for one thing: she signals this was her personal experience and frames it as a past dosing level she has moved away from. That's honest. She's not telling viewers to dose at 80 units.

What she gets wrong, or at least dangerously imprecise about, is using "units" without any clarification of vial concentration. Without knowing the concentration of the compounded vial, 80 units is a meaningless number. It could represent a safe dose or a dangerous one. The Institute for Safe Medication Practices has flagged unit-based confusion with non-insulin injectables as a recurring source of overdose risk. A 2023 FDA safety communication specifically warned about dosing errors with compounded semaglutide products tied to concentration misunderstandings. Repeating this framing to 34,800 viewers, without clarification, is a problem regardless of intent.

What should you actually know?

If you are using or considering compounded semaglutide or tirzepatide, the measurement system matters more than the number. Always confirm the concentration of your compounded vial in mg per mL with your prescribing clinician before drawing any dose. A dose described only in "units" without a known concentration is not a safe reference point.

Compounded GLP-1 medications are not FDA-approved and are not equivalent to brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. They may be legal to prescribe under shortage provisions, but they have not undergone the same manufacturing and efficacy review. The FDA has issued multiple warnings about compounded semaglutide quality since 2023. If your provider or an online source is describing your GLP-1 dose in units without specifying concentration, that is a red flag worth raising before your next injection.

• Always verify the mg/mL concentration of any compounded GLP-1 vial with a licensed prescriber.
• Dosing errors with compounded injectables have been reported to the FDA. Report adverse events at MedWatch.
• "Affordable" compounded GLP-1s vary widely in quality, concentration, and regulatory oversight.